Proteomics leadership CDI Labs offers world-class proteome-wide platforms (HuProt, PhIP-Seq variants) and deep proteomics bench expertise, presenting a compelling value proposition for pharma and biotech teams needing comprehensive biomarker discovery, target identification, and protein manufacturing capabilities.

Full-cycle services Their solutions span basic research through clinical deployment, enabling end-to-end support for customers pursuing autoantibody biomarker discovery, immunogenicity assessment, and validation workflows, which can streamline vendor consolidation and reduce project timelines.

Expanded capabilities Recent launch of VirScan, HuScan, and MouseScan services expands repertoire for antigen-specific profiling, viral exposure mapping, and immune repertoire analyses, offering cross-sell opportunities to drug discovery programs and infectious disease projects.

Scale and reach With the HuProt array covering thousands of human proteins and partnerships across North America, CDI Labs can position as a go-to CRO for large-scale proteome-based screening, target ID, and monoclonal antibody development for diverse therapeutic modalities.

Growth signals Revenue range and prior funding indicate a growth-stage biotech services provider; prospects include expanding collaborations with mid-sized biotechs seeking specialized proteomics services, GMP-like validation pathways, and potential geographic expansion partnerships.